Discovery of the First Angiogenic Factor

Foundations | Discovery of the First Angiogenic Factor Courtesy of Judah Folkman During the mid-1970s to early 1980s, my laboratory was trying to isolate an angiogenic stimulator from tumors, the factor we called TAF [tumor angiogenic factor] in our notebooks. This was at a time when no angiogenic stimulators were known to exist, nor had any angiogenesis inhibitors been discovered. In fact, few, if any, colleagues believed that angiogenic proteins would ever be found. "We used tumors grow

Written byJudah Folkman
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

During the mid-1970s to early 1980s, my laboratory was trying to isolate an angiogenic stimulator from tumors, the factor we called TAF [tumor angiogenic factor] in our notebooks. This was at a time when no angiogenic stimulators were known to exist, nor had any angiogenesis inhibitors been discovered. In fact, few, if any, colleagues believed that angiogenic proteins would ever be found.

"We used tumors grown in mice, and the purification procedure involved multiple steps, which took more than a month to complete a purification cycle. We could not obtain a pure protein, despite more than four years of work.

"Then, in early 1983, Michael Klagsbrun, an associate professor in my laboratory, and Yuen Shing, a new assistant professor, [both postdoctoral fellows when the project started] introduced a heparin Sepharose column into the procedure and almost immediately obtained a single band of purified protein, purified approximately 500,000-fold (Arrow).

"This was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies